NCT05485779View on ClinicalTrials.gov

SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

July 10, 2023

Conditions
Eosinophilic Esophagitis (EoE)
Interventions
DRUG

AQ280

"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"

DRUG

Placebo

"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"

Trial Locations (1)

LS2 9LH

Fortrea Clinical Research Unit Ltd., Leeds

All Listed Sponsors
lead

AQILION AB

INDUSTRY